JW Pharmaceutical Corp (001067) — Cash Flow Quality Index

Latest as of September 2025: 1.53x

JW Pharmaceutical Corp (001067) has a Cash Flow Quality Index of 1.53x as of September 2025. Operating cash flow of ₩46.92 Billion exceeds net income of ₩30.59 Billion, indicating high earnings quality where cash backs reported profits. Explore JW Pharmaceutical Corp (001067) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

1.53x
Operating CF / Net Income

Operating Cash Flow

₩46.92 Billion
KRW

Net Income

₩30.59 Billion
KRW

Data as of

Sep 2025
Most recent filing

JW Pharmaceutical Corp Cash Flow Quality Index (2015–2024)

Historical Cash Flow Quality Index for JW Pharmaceutical Corp across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 001067 cash generation efficiency.

Annual Cash Flow Quality Index for JW Pharmaceutical Corp (2015–2024)

Year-by-year earnings quality comparison for JW Pharmaceutical Corp.

Year Quality Index Operating CF (KRW) Net Income YoY Change
2024 1.22x ₩79.39 Billion ₩65.04 Billion ▼ -51.2%
2023 2.50x ₩87.16 Billion ₩34.84 Billion ▲ +47.8%
2022 1.69x ₩56.76 Billion ₩33.55 Billion ▼ -73.8%
2018 6.47x ₩52.11 Billion ₩8.06 Billion ▲ +403.9%
2015 -2.13x ₩-4.17 Billion ₩1.96 Billion
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.